Overview
Background
Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.
Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.
Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.
The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.
Availability
- Associate Professor Colm Keane is:
- Available for supervision
Qualifications
- Masters (Coursework) of Business Administration, Griffith University
- Doctor of Philosophy, Griffith University
Research interests
-
Tumour Immunology
-
DLBCL
-
Primary CNS Lymphoma
-
Hodgkin Lymphoma
-
Viral Associated Lymphomas
Works
Search Professor Colm Keane’s works on UQ eSpace
2024
Journal Article
Intra‐tumoral and peripheral blood <scp>TIGIT</scp> and <scp>PD</scp>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Snell, Cameron, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Shanavas, Mohamed, Blyth, Emily, Steidl, Christian, Savage, Kerry, Farinha, Pedro ... Gandhi, Maher K. (2024). Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology. doi: 10.1002/ajh.27459
2024
Conference Publication
First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study
Chong, Geoffrey, Palmer, Jodie, Barraclough, Allison, Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza Anne (2024). First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.tps7092
2024
Conference Publication
First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study
Chong, Geoffrey, Lee, Denise, Lee, Sze Ting, Grobler, Anneke, Khor, Richard, Campbell, Belinda A., Thachil, Thanuja, Manos, Kate, Martynchyk, Arina, Douglas, Genevieve, Keane, Colm, Palmer, Jodie and Hawkes, Eliza Anne (2024). First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7070
2024
Conference Publication
A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Peter, Borchmann, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Torzan, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7056
2024
Conference Publication
A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis
Timmerman, John, Lavie, David, Peter, Borchmann, Gregory, Gareth P., Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Johnson, Nathalie A. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7055
2024
Journal Article
Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance
Wight, Joel, Blombery, Piers, Lickiss, Jennifer, Burgess, Melinda, Gould, Clare, Minson, Adrian, Swain, Fiona, Sabdia, Muhammed B., Gandhi, Maher K., Birchley, Andrew, Keane, Colm and Hawkes, Eliza A (2024). Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance. Haematologica, 109 (9), 3013-3018. doi: 10.3324/haematol.2023.284600
2024
Journal Article
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
Barraclough, Allison, Agrawal, Shivam, Talaulikar, Dipti, Chong, Geoffrey, Yoo, Edward, Cheah, Chan Y., Franco, Nunzio, Nguyen, Bianca, Mutsando, Howard, Tahir, Fatima, Trotman, Judith, Huang, Jing, Keane, Colm, Lincoln, Mitchel, Cochrane, Tara, Johnston, Anna M., Dickinson, Michael, Opat, Stephen, McQuilten, Zoe K., Wood, Erica M., St George, Gayathri and Hawkes, Eliza A. (2024). Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica, 109 (10), 3338-3345. doi: 10.3324/haematol.2023.284538
2024
Journal Article
Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Shaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan Y, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoffrey, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A. (2024). Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. eJHaem, 5 (2), 325-332. doi: 10.1002/jha2.870
2024
Journal Article
Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment
Alim, Louisa F., Keane, Colm and Souza-Fonseca-Guimaraes, Fernando (2024). Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Current Opinion in Immunology, 86 102409. doi: 10.1016/j.coi.2023.102409
2024
Journal Article
Epstein–Barr virus‐associated lymphomas decoded
Bednarska, Karolina, Chowdhury, Rakin, Tobin, Joshua W. D., Swain, Fiona, Keane, Colm, Boyle, Stephen, Khanna, Rajiv and Gandhi, Maher K. (2024). Epstein–Barr virus‐associated lymphomas decoded. British Journal of Haematology, 204 (2), 415-433. doi: 10.1111/bjh.19255
2023
Conference Publication
Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182128
2023
Conference Publication
Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182019
2023
Conference Publication
Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study
Chong, Geoff, Palmer, Jodie B., Barraclough, Allison A., Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza A. (2023). Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-173110
2023
Journal Article
Prognostic markers within the tumour microenvironment in classical Hodgkin lymphoma
Martynchyk, Arina, Chowdhury, Rakin, Hawkes, Eliza A. and Keane, Colm (2023). Prognostic markers within the tumour microenvironment in classical Hodgkin lymphoma. Cancers, 15 (21) 5217, 1-21. doi: 10.3390/cancers15215217
2023
Journal Article
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia
Cass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007
2023
Conference Publication
Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Anti–PD-1–naive Relapsed Or Refractory Classical Hodgkin Lymphoma
Johnson, Nathalie, Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Anti–PD-1–naive Relapsed Or Refractory Classical Hodgkin Lymphoma. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971156.02746.02
2023
Conference Publication
Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Anti–PD-1 Treatment
Timmerman, John, Lavie, David, Johnson, Nathalie, Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Luigi Zinzani, Pier, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Anti–PD-1 Treatment. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971168.59900.67
2023
Conference Publication
T Cell CD62L Expression Following Nivolumab Therapy Is Associated With Long Term Response To Rituximab-nivolumab In Treatment Naïve Follicular Lymphoma: Results From The 1st Flor Study
Koldej, Rachel, Barraclough, Allison, Ting Lee, Sze, Morgan, Huw, Holzwart, Nicholas, Koshy, Minu, Smith, Charmaine, Chong, Geoff, Gilbertson, Michael, Keane, Colm, Ting, Stephen, Churilov, Leonid, Ritchie, David and Hawkes, Eliza A. (2023). T Cell CD62L Expression Following Nivolumab Therapy Is Associated With Long Term Response To Rituximab-nivolumab In Treatment Naïve Follicular Lymphoma: Results From The 1st Flor Study. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971812.42966.2d
2023
Conference Publication
Polatuzumab, Bendamustine & Rituximab (POLA-BR) Efficacy In Relapsed/refractory Diffuse Large B Cell Lymphoma (RRDLBCL) Trial-ineligible Patients: An Australian Lymphoma Registry (LARDR) Study
Shaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoff, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A (2023). Polatuzumab, Bendamustine & Rituximab (POLA-BR) Efficacy In Relapsed/refractory Diffuse Large B Cell Lymphoma (RRDLBCL) Trial-ineligible Patients: An Australian Lymphoma Registry (LARDR) Study. EHA2023, Online, 8 - 15 June 2023. Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/01.hs9.0000971668.24670.ab
2023
Journal Article
C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients
Bonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.13993
Funding
Current funding
Past funding
Supervision
Availability
- Associate Professor Colm Keane is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma
Principal Advisor
Other advisors: Dr Arutha Kulasinghe, Dr Zachary Hawula
-
Doctor Philosophy
Investigating the mechanisms of immune evasion in relapsed/refractory DLBCL
Principal Advisor
Other advisors: Dr Zachary Hawula
-
Doctor Philosophy
Investigation of immune responses to novel and standard therapies in DLBCL
Principal Advisor
Other advisors: Dr Joshua Tobin, Associate Professor Fernando Guimaraes
-
Doctor Philosophy
Impact of genetics upon the tumour microenvironment in Follicular Lymphoma
Associate Advisor
Other advisors: Dr Joshua Tobin, Dr Soi Law, Professor Maher Gandhi
-
Master Philosophy
Amyloidosis Monitoring and Outcomes in an Australian Tertiary Centre
Associate Advisor
-
Doctor Philosophy
Reversing tumour necrosis factor-mediated immunosuppression to boost immunity against experimental CD19+ blood cancers
Associate Advisor
Other advisors: Dr Allie Lam, Associate Professor Fernando Guimaraes
Completed supervision
-
2022
Doctor Philosophy
A Comprehensive Study of Intratumoural T-cells in Follicular Lymphoma
Associate Advisor
Other advisors: Dr Soi Law, Professor Maher Gandhi
-
2021
Doctor Philosophy
Clinical and Prognostic Tools to Improve Frontline Management Strategies in Follicular Lymphoma
Associate Advisor
Other advisors: Professor Maher Gandhi
-
2020
Doctor Philosophy
The impact of deficient antigen presentation on the tumour microenvironment of diffuse large B cell lymphoma
Associate Advisor
Other advisors: Professor Maher Gandhi
-
2019
Doctor Philosophy
A LABORATORY STUDY OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Associate Advisor
Other advisors: Professor Maher Gandhi
Media
Enquiries
For media enquiries about Associate Professor Colm Keane's areas of expertise, story ideas and help finding experts, contact our Media team: